Literature DB >> 8958805

Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas.

M Saegusa1, Y Kamata, M Isono, I Okayasu.   

Abstract

A total of 103 endometrial carcinomas (endometrioid type), as well as 15 samples of normal (atrophic or proliferative phase) and 26 of hyperplastic endometrium, were immunohistochemically investigated for expression of Bcl-2, and oestrogen and progesterone receptors (ER and PR), and the results compared with findings for apoptosis and cell proliferation. Carcinoma cases were subdivided into tubular and solid components on the basis of tumour growth patterns. Immunopositivity for Bcl-2, ER, and PR in tubular components was significantly higher than in the solid category, being negatively associated with histological grading. Immunoreactivity scores revealed that Bcl-2 in the tubular group was positively correlated with PR but not ER, while its expression in normal and hyperplastic endometrium was closely linked with both. Apoptotic and mitotic indices (AI and MI) were both significantly lower in tubular than in solid areas. In the tubular areas, AI, values were significantly lower in the subgroup with a high level of Bcl-2 expression than in either low-level or negative groups. These results indicate that Bcl-2 expression may play a central role in the inhibition of apoptosis in endometrial carcinoma, in particular those cases with tubular components, possibly being associated with PR rather than ER. Changes in the propensity for apoptosis may be related to alterations of tumour growth pattern and of features of differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958805     DOI: 10.1002/(SICI)1096-9896(199611)180:3<275::AID-PATH660>3.0.CO;2-A

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  Squamous morules are functionally inert elements of premalignant endometrial neoplasia.

Authors:  Ming-Chieh Lin; Lesley Lomo; Jan P A Baak; Charis Eng; Tan A Ince; Christopher P Crum; George L Mutter
Journal:  Mod Pathol       Date:  2008-09-19       Impact factor: 7.842

Review 2.  Histopathological evaluation of apoptosis in cancer.

Authors:  Y Soini; P Pääkkö; V P Lehto
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

3.  Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings.

Authors:  M Saegusa; I Okayasu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells.

Authors:  Makoto Saegusa; Miki Hashimura; Takeshi Kuwata; Mieko Hamano; Isao Okayasu
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

5.  Apoptotic activity is increased in parallel with the metaplasia-dysplasia-carcinoma sequence of the bronchial epithelium.

Authors:  U Törmänen; K Nuorva; Y Soini; P Pääkkö
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

6.  Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.

Authors:  M Saegusa; D Machida; I Okayasu
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  DCC expression is related to mucinous differentiation but not changes in expression of p21(WAF1/Cip1) and p27Kip1, apoptosis, cell proliferation and human papillomavirus infection in uterine cervical adenocarcinomas.

Authors:  M Saegusa; I Okayasu
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 8.  New concepts for an old problem: the diagnosis of endometrial hyperplasia.

Authors:  Peter A Sanderson; Hilary O D Critchley; Alistair R W Williams; Mark J Arends; Philippa T K Saunders
Journal:  Hum Reprod Update       Date:  2017-03-01       Impact factor: 15.610

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.